Overview

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2028-01-29

Target enrollment:

Participant gender:

Summary

A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)

Phase:

PHASE3

Details

Lead Sponsor:

Zai Lab (Shanghai) Co., Ltd.